Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotechnology company focused on correcting abnormal gene expression, announced its participation in two upcoming investor conferences in February and March 2025.
The company will join the B. Riley Securities Precision Oncology and Radiopharma Conference on February 28, 2025, where President and CEO Adrian Gottschalk will participate in a Synthetic Lethality Panel at 9 a.m. EST in New York.
Additionally, Foghorn will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 2:30 p.m. EST in Boston, with management also conducting virtual one-on-one meetings that day.
Webcasts of the presentations will be available under the "Events & Presentations" section of Foghorn's website for 90 days. The company's Gene Traffic Control® platform focuses initially on oncology with potential applications across a wider spectrum of diseases.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FHTX declined 1.16%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference, and at the TD Cowen 45th Annual Health Care Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
B. Riley Securities Precision Oncology and Radiopharma Conference
- Synthetic Lethality Panel: Friday, February 28, 2025, at 9 a.m. EST in New York, NY
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
TD Cowen 45th Annual Health Care Conference
- Presentation: Monday, March 3, 2025, at 2:30 p.m. EST in Boston, MA
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in virtual one-on-one meetings on Monday, March 3, 2025
A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 90 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ
When will Foghorn Therapeutics (FHTX) present at the TD Cowen Health Care Conference in 2025?
What investor conferences is Foghorn Therapeutics (FHTX) attending in February-March 2025?
Who will represent Foghorn Therapeutics (FHTX) at the upcoming investor conferences?
Where can investors access the webcast of Foghorn Therapeutics' (FHTX) conference presentations?
What is the focus of Foghorn Therapeutics' (FHTX) Gene Traffic Control platform?
